The global blood screening market was valued at USD 3.4 billion in 2024 and is projected to reach USD 4.2 billion in 2026 and USD 6.6 billion by 2030, expanding at a CAGR of 11.9% from 2025 to 2030. North America dominated the global market in 2024, accounting for 38.4% of total revenue.

The market is expanding as the number of blood donations increases worldwide, creating a greater need for reliable screening technologies to ensure the safety of donated blood and detect transfusion-transmissible infections. Growing healthcare expenditure, rising awareness of blood safety, technological advancements, and government initiatives are also supporting market development.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

Blood Screening Market: Key Highlights

• 2024 Market Size: USD 3.4 billion
• 2026 Market Size: USD 4.2 billion
• 2030 Market Size: USD 6.6 billion
• CAGR (2025–2030): 11.9%
• Largest Regional Market: North America
• North America Revenue Share (2024): 38.4%
• Fastest-Growing Region: Asia Pacific
• Asia Pacific CAGR: 13.7%

Go Deeper! Ask Prism AI

about the Global blood screening market. Get instant answers to questions related to market sizing, growth drivers & their impact, and more.

Key Market Trends & Insights

North America Leads the Global Market

North America accounted for the largest share of the global blood screening market in 2024, representing 38.4% of revenue. The region benefits from established blood donation and transfusion infrastructure, advanced diagnostic technologies, high healthcare expenditure, and stringent blood safety requirements.

Asia Pacific Shows Strong Growth Potential

The Asia Pacific blood screening market is projected to expand at a 13.7% CAGR during the forecast period. Increasing blood donation activities, improving healthcare infrastructure, growing awareness of transfusion safety, and rising investments in advanced diagnostic technologies are contributing to regional growth.

Nucleic Acid Amplification Tests Hold a Leading Position

Based on technology, nucleic acid amplification tests (NAT) accounted for the largest market share in 2024, representing 41.2% of revenue. NAT enables the detection of genetic material from infectious pathogens and can help identify infections at an earlier stage, strengthening its role in blood safety and transfusion screening.

Reagents Account for the Largest Product Share

Based on product, the reagents segment dominated the market in 2024, accounting for 73.4% of revenue. The high utilization of reagents across blood screening workflows and the recurring requirement for screening and diagnostic testing support the segment's leading position.

Download a free sample report or claim your copy of this full market intelligence report

Blood Screening Market Growth Drivers

Several factors are contributing to the expansion of the global blood screening market.

Increasing Blood Donations

The rising number of blood donations worldwide is a major market growth driver. As blood donation volumes increase, healthcare organizations and blood banks require effective screening solutions to identify infectious diseases and minimize the risk of transfusion-transmissible infections.

Rising Prevalence of Infectious Diseases

The continued prevalence of infectious diseases increases the need for effective screening of donated blood. Screening technologies that can rapidly and accurately detect pathogens are becoming increasingly important for maintaining blood safety.

Technological Advancements

Advances in automation, molecular diagnostics, and nucleic acid-based testing platforms are improving the speed, accuracy, and efficiency of blood screening. Automated workflows can also support higher testing volumes while reducing manual intervention.

Government Blood Safety Initiatives

Government regulations and initiatives focused on improving blood safety are encouraging healthcare institutions and blood banks to adopt reliable screening technologies. Regulatory emphasis on detecting transfusion-transmissible infections supports continued demand for advanced screening solutions.

Growing Awareness of Safe Blood Transfusion

Greater public and healthcare-sector awareness of blood safety is encouraging stronger screening practices. Increased understanding of the risks associated with contaminated or inadequately screened blood is supporting the adoption of comprehensive screening protocols.

Increasing Healthcare Expenditure

Growing healthcare expenditure across developed and emerging economies is facilitating investments in advanced diagnostic infrastructure, laboratory equipment, and blood screening services. This trend is particularly relevant in regions where healthcare systems are expanding their diagnostic capabilities.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

Understanding Blood Screening

Blood screening is a critical medical process used to analyze blood samples for infectious agents, abnormalities, and other clinically relevant indicators. In the context of transfusion medicine, screening helps identify potentially harmful infections and supports the safety of donated blood before it is administered to patients.

Blood-based testing can also provide information about various aspects of an individual's health, including blood cell counts and chemical markers such as glucose and cholesterol. These assessments can support the detection and management of conditions including anemia, diabetes, infections, and cardiovascular disorders.

For blood banks and transfusion services, screening is particularly important because it helps reduce the risk of transmitting infections through donated blood. The integration of molecular testing, automation, and advanced diagnostic platforms is further improving the efficiency and reliability of screening workflows.

Emerging Opportunities in the Blood Screening Market

The convergence of molecular diagnostics, laboratory automation, digital technologies, and preventive healthcare is creating new opportunities across the blood screening industry.

The aging global population is also contributing to demand for healthcare services, as older populations tend to have a higher prevalence of chronic and other medical conditions requiring diagnostic evaluation. At the same time, expanding healthcare infrastructure in emerging economies is creating opportunities for the adoption of modern blood screening technologies.

The continued development of high-throughput and automated screening platforms may further improve laboratory productivity and enable healthcare providers to process larger volumes of blood samples efficiently.

Blood Screening Market Size & Forecast

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Competitive Landscape

The blood screening market includes global diagnostic, life sciences, and healthcare technology companies developing screening systems, reagents, molecular testing platforms, and related solutions. Competition is shaped by technological innovation, product portfolios, regulatory compliance, testing accuracy, automation capabilities, and global distribution networks.

Key Blood Screening Companies

• Abbott
• Danaher Corporation (Beckman Coulter)
• Becton Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Hoffman-La Roche Ltd.
• Grifols, S.A.
• Ortho-Clinical Diagnostics, Inc.
• Siemens Healthcare GmbH
• Thermo Fisher Scientific, Inc.

Explore our dedicated business services:

U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today